Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
The latest analyst coverage could presage a bad day for Co-Diagnostics, Inc. (NASDAQ:CODX), with the analysts making...
Coronavirus test maker Co-Diagnostics reported disappointing third-quarter metrics and CODX stock crumbled on Tuesday. Moderna inked a supply deal for its coronavirus vaccine in the UK.
Shares of Co-Diagnostics (NASDAQ: CODX) were getting clobbered on Tuesday, with the stock down 15.9% as of 12:02 p.m. EST. Although Co-Diagnostics reported huge revenue and earnings growth, its earnings per share of $0.53 missed the consensus analyst estimate of $0.63 per share. What does matter is Co-Diagnostics' growth prospects and whether or not the valuation of the healthcare stock already reflects those prospects.
Tesla and China's Joyy moved toward buy points, while Walgreens dragged on the Dow Jones today as stock futures geared for a mixed start.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart™ SARS-CoV-2 (genes RdRp/E) multiplex test for multiple targets of the SARS-CoV-2 genome have both obtained regulatory authorization to be sold as in vitro diagnostics ("IVD") for the diagnosis of COVID-19 in markets that accept CE-markings, and are now avai...
Shares of Co-Diagnostics (NASDAQ:CODX) decreased 22.88% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were up 630.00% over the past year to $0.53, which missed the estimate of $0.63.Revenue of $21,819,000 up by 52559.65% year over year, which missed the estimate of $32,790,000.Outlook Co-Diagnostics hasn't issued any earnings guidance for the time being.Co-Diagnostics hasn't issued any revenue guidance for the time being.Details Of The Call Da...
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2020 and provided updates on Company developments, including receipt of CE markings for both the recently developed Logix Smart ABC (Influenza A/B, SARS-CoV-2) test kit for simultaneous detection of Influenza A, Influenza B, and SARS-CoV-2 and Logix Smart SARS-CoV-2 (gen...